Summit Therapeutics Company Insiders
SMMT Stock | USD 18.94 0.26 1.35% |
Summit Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Summit Therapeutics PLC suggests that vertually all insiders are extremely bullish. Summit Therapeutics employs about 105 people. The company is managed by 24 executives with a total tenure of roughly 245 years, averaging almost 10.0 years of service per executive, having 4.38 employees per reported executive.
Summit Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-03-26 | Mahkam Zanganeh | Acquired 30000 @ 3.75 | View | ||
2023-12-13 | Ankur Dhingra | Acquired 20400 @ 2.17 | View | ||
2023-12-12 | Mahkam Zanganeh | Acquired 5000 @ 2.07 | View |
Monitoring Summit Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Summit |
Summit Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Summit Therapeutics' future performance. Based on our forecasts, it is anticipated that Summit will maintain a workforce of slightly above 200000 employees by December 2024.Summit Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3147) % which means that it has lost $0.3147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7321) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.91 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.Common Stock Shares Outstanding is likely to gain to about 650.6 M in 2024, despite the fact that Net Loss is likely to grow to (67.4 M).
Summit Therapeutics Workforce Comparison
Summit Therapeutics PLC is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 606. Summit Therapeutics retains roughly 105 in number of employees claiming about 17% of equities under Health Care industry.
Summit Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Summit Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 1.0 | 1 | 1 | 315,681 | 315,681 |
2024-06-01 | 6.0 | 6 | 1 | 2,143,198 | 0.00 |
2023-12-01 | 4.0 | 8 | 2 | 29,795,283 | 805,495 |
2022-06-01 | 1.5 | 3 | 2 | 1,021,135 | 20,000 |
2021-12-01 | 9.0 | 9 | 1 | 696,541 | 112,500 |
2021-03-01 | 6.0 | 6 | 1 | 191,096 | 5,110 |
2020-12-01 | 1.0909 | 12 | 11 | 26,879,431 | 147,426 |
Summit Therapeutics Notable Stakeholders
A Summit Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Summit Therapeutics often face trade-offs trying to please all of them. Summit Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Summit Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MBA DDS | President CoCEO | Profile | |
Robert Duggan | CoCEO Chairman | Profile | |
Manmeet CPA | CFO COO | Profile | |
Manmeet Soni | COO Director | Profile | |
Elaine JD | Head Counsel | Profile | |
Fong Clow | Chief Officer | Profile | |
Betty Chang | Oncology Research | Profile | |
Bhaskar Anand | Chief Finance | Profile | |
Will Black | Head Technology | Profile | |
Laura MD | Senior Development | Profile | |
Campbell Hair | Head HR | Profile | |
FRS DBE | Chairman CoFounder | Profile | |
DDS MBA | Pres CoCEO | Profile | |
Anne Heatherington | Head Sciences | Profile | |
Dave Gancarz | Chief Officer | Profile | |
Ankur Dhingra | Chief Officer | Profile | |
Shelley Spray | Chief Officer | Profile | |
Juthamas Sukbuntherng | Head DMPK | Profile | |
Andrew Dwyer | Head Chain | Profile | |
Michelle Avery | Director Relations | Profile | |
Urte Gayko | Quality Regulatory | Profile | |
Divya Chari | Head Operations | Profile | |
Noam MBA | Senior Affairs | Profile | |
Abby Murphy | Head Resources | Profile |
About Summit Therapeutics Management Performance
The success or failure of an entity such as Summit Therapeutics PLC often depends on how effective the management is. Summit Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Summit management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Summit management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (3.06) | (2.91) | |
Return On Capital Employed | (0.49) | (0.52) | |
Return On Assets | (3.03) | (2.88) | |
Return On Equity | (7.91) | (7.52) |
Please note, the imprecision that can be found in Summit Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Summit Therapeutics PLC. Check Summit Therapeutics' Beneish M Score to see the likelihood of Summit Therapeutics' management manipulating its earnings.
Summit Therapeutics Workforce Analysis
Traditionally, organizations such as Summit Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Summit Therapeutics within its industry.Summit Therapeutics Manpower Efficiency
Return on Summit Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 5.9M | |
Net Loss Per Executive | 25.6M | |
Working Capital Per Employee | 1.6M | |
Working Capital Per Executive | 7.1M |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.